THERAPEUTIC ANTIBODY-DRUG CONJUGATES DRUG DEVELOPMENT PROGRAM
Antibody-drug conjugates (ADCs) are a new class of highly potent biopharmaceutical drugs designed as a targeted therapy for the treatment of cancer. By combining the unique targeting capabilities of monoclonal antibodies with the cancer-killing ability of cytotoxic drugs, antibody-drug conjugates allow sensitive discrimination between healthy and diseased tissue.
MULTICELL IMMUNOTHERAPEUTICS, INC. (MCIT)
We licensed exclusive rights to three ADCs that MCIT will prepare for our further evaluation as prospective therapeutics for the treatment of triple-negative breast cancer, as well as multiple myeloma and associated osteolytic bone disease.
MCIT’s ADC platform technology is based on unique multivalent, cleavable linkers that allow drugs tethered to the antibody to be released intracellularly or extracellularly upon the binding of the antibody to the target cell. Additionally, the MCIT’s ADC technology platform allows multiple drugs to be attached per targeting antibody and to release the drugs in their original form without modification of the drug.
MultiCell Technologies (OTCPK: MCET) subsidiary MultiCell Immunotherapeutics enters into a research and development and product license agreement with Oxis Biotech (OTCQB: OXIS) to create three novel antibody-drug conjugates (ADCs) based on Oxis' lead drug candidates and MultiCell's proprietary ADC platform technology. The ADCs will be targeted for the treatment of triple-negative breast cancer and multiple myeloma and associated osteolytic lesions.
Under the terms of the agreement, Oxis will pay MultiCell a license fee of $500K, up to $12.75M in clinical development milestones and a royalty of 3% on net sales. Oxis will also reimburse MultiCell up to $1.125M in development costs. MultiCell grants Oxis an option to purchase manufacturing rights to the three ADCs upon the payment of an additional $10M.
MultiCell retains all rights to its ADC platform for all indications and is free to pursue its own drug development programs and to partner with other firms.
$MCET Xenogenics Corporation (A Subsidiary of Multicell Technologies, Inc.) Increasing Artery Related Health Issues Boosting The Global Bioabsorbable Stents Market
Jun 28, 2016 According to a recently published report, the global Bioabsorbable Stents Market is expected to grow $2800 million till 2022 with the CAGR of 44.7% during 2016-2022. The segmentation of global bioabsorbable stents market is based on absorption rate, drugs, applications, end users, materials and regional outlook. The report on global bioabsorbable stents market forecast 2016-2022 (absorption rate, drugs, applications, end users, materialsand regional outlook) provides detailed overview and predictive analysis of the market.
There has been huge demand forbioabsorbable stents. Unhealthy and hectic lifestyle is cause for increase in the rate of coronary artery diseases across the globefrom last few years.Increasing geriatric population andgrowing prevalence of obesity are adding significantly to the severity of increasing coronary artery diseases. Therising incidences of cardiovascular diseases and increasing number of people who had gone through bariatricsurgery are some of the major growth factors boosting the bioabsorbable stents market. Cardiovascular diseases are characterized by abnormalityof the heart and blood vessels. The major disorders such as coronary heart disease,rheumatic heart disease and cerebrovascular disease are at risk of cardiovascular diseaseswhich is being caused by the rising obesity and increase in blood pressure. According to World Health Organization, around 17.5 million people die from cardiovascular diseases every year across the globe.Growing prevalence rate of heart related diseases and rising incidences of heart attacks, strokes and obesity related diseases are pushing the global bioabsorbable stents market. Stent is a device, which is inserted into the artery or blood vessels to expand the vessel and stop the blockage.
Scope of the report
1. Global Bioabsorbable Stents Market By Absorption Rate 2012 - 2022 ($ million) 1.1. Slow absorption stents 1.2. High absorption stents
2. Global Bioabsorbable Stents Market By Drugs 2012 - 2022 ($ million) 2.1. Paclitaxel 2.2. Limus based drugs
3. Global Bioabsorbable Stents Market By Applications 2012 - 2022 ($ million) 3.1. Coronary artery disease 3.2. Peripheral artery disease
4. Global Bioabsorbable Stents Market By End Users 2012 - 2022 ($ million) 4.1. Hospitals 4.2. Cardiac centers 5. Global Bioabsorbable Stents Market By Materials 2012 - 2022 ($ million) 5.1. Polymeric stents 5.2. Metallic stents
6. Global Bioabsorbable Stents Market Regional Outlook 2012-2022($ million) 6.1. North America 6.2. Europe 6.3. Asia Pacific 6.4. Rest of the world
Market Data 
Markets 
AI
